NCT00148447

The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia

Placebo-Controlled Trial of Cipralex in the Treatment of Negative Symptoms in Schizophrenia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 40 (planned)
• Sponsor: BeerYaakov Mental Health Center · Other Government
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to evaluate the therapeutic effect of escitalopram in the treatment of negative symptoms in schizophrenia patients in a double-blind placebo-controlled study.

Detailed description

The aim of this study is to evaluate the therapeutic effect of escitalopram (cipralex) in the treatment of negative symptoms in schizophrenic patients receiving either typical or the newer atypical antipsychotics (olanzapine and risperidone) in a double-blind placebo-controlled study. As there is no drug treatment that is considered as first-line treatment in the treatment of negative symptoms, we thought that the comparison with placebo is plausible. However, it is important to note that the patients will receive the commonly used treatment for their disorder (i.e. antipsychotic medication).

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	escitalopram

Timeline

• Start date: 2004-11-01
• Completion: 2005-09-01
• First posted: 2005-09-08
• Last updated: 2007-05-03

Locations

1 site across 1 country: Israel